Relationship between preoperative platelet-to-lymphocyte ratio and prognosis in patients with pancreatic ductal adenocarcinoma: a meta-analysis_West China Medical Journal

Authors：

HE Dong , FAN Wanli , ZHANG Shuze , ZHAO Bin ,  CHENG Zhibin

Department of General Surgery, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P. R. China;

Corresponding author：

CHENG Zhibin, Email: zhibin_cheng@hotmail.com

Keywords：

Pancreatic ductal adenocarcinoma; prognosis; platelet-to-lymphocyte ratio; meta-analysis

DOI：

10.7507/1002-0179.202312043

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the relationship between preoperative platelet-to-lymphocyte ratio (PLR) and prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). Methods Studies on the relationship between preoperative PLR and prognosis of PDAC patients were retrieved from China National Knowledge Infrastructure, Chongqing VIP, SinoMed, Wanfang, PubMed, Embase, Web of Science, and Cochrane Library, with a search period from databases establishment to December 2023. A meta-analysis was conducted using RevMan 5.3 software. Results A total of 7 studies were included, including 1273 patients. The meta-analysis results showed that the postoperative overall survival [hazard ratio (HR)=1.69, 95% confidence interval (CI) (1.24, 2.30)] and disease-free survival [HR=1.83, 95%CI (1.49, 2.24)] of PDAC patients with high preoperative PLR were shortened (P<0.05). The results of subgroup analysis showed that when the cut off of PLR was<200, preoperative high PLR was associated with shortened overall survival (HR=1.91, P<0.05), but when the cut off of PLR was ≥200, there was no significant correlation between preoperative PLR and overall survival (P>0.05). When followed up for<3 years, preoperative high PLR was associated with shortened overall survival (HR=2.05, P<0.05), but when followed up for ≥3 years, there was no significant correlation between preoperative PLR and overall survival (P>0.05). Conclusion Current evidence suggests that preoperative high PLR may be a risk factor for poor prognosis in PDAC patients.

Citation： HE Dong, FAN Wanli, ZHANG Shuze, ZHAO Bin, CHENG Zhibin. Relationship between preoperative platelet-to-lymphocyte ratio and prognosis in patients with pancreatic ductal adenocarcinoma: a meta-analysis. West China Medical Journal, 2024, 39(5): 771-775. doi: 10.7507/1002-0179.202312043 Copy

1.	王海静, 秦芳. 外周血FAR联合NLR在局部晚期或转移性胰腺癌患者预后评估中的价值. 国际检验医学杂志, 2022, 43(13): 1587-1592, 1597.
2.	Toledano-Fonseca M, Cano MT, Inga E, et al. The combination of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio with liquid biopsy biomarkers improves prognosis prediction in metastatic pancreatic cancer. Cancers (Basel), 2021, 13(6): 1210.
3.	Gleisner AL, Assumpcao L, Cameron JL, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?. Cancer, 2007, 110(11): 2484-2492.
4.	Klein F, Puhl G, Guckelberger O, et al. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol Res Pract, 2012, 2012: 939350.
5.	Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol, 2007, 14(1): 118-127.
6.	Chen X, Yi B, Liu Z, et al. Global, regional and national burden of pancreatic cancer, 1990 to 2017: results from the Global Burden of Disease Study 2017. Pancreatology, 2020, 20(3): 462-469.
7.	Singh N, Baby D, Rajguru JP, et al. Inflammation and cancer. Ann Afr Med, 2019, 18(3): 121-126.
8.	Sideras K, Braat H, Kwekkeboom J, et al. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev, 2014, 40(4): 513-522.
9.	Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst, 2014, 106(6): dju124.
10.	钱佳璐, 汤娜. 血小板与淋巴细胞比值联合CA19-9预测胰腺癌预后. 现代消化及介入诊疗, 2022, 27(4): 512-515.
11.	谢小妹, 陈龙, 黄江琼, 等. 术前血清CEA水平与非小细胞肺癌预后关系的Meta分析. 现代生物医学进展, 2012, 12(19): 3689-3692.
12.	唐伟杰. NLR和PLR对根治性胰腺癌切除术术后生存期的预测价值. 芜湖: 皖南医学院, 2022.
13.	申鹏. 术前NLR、PLR对胰腺癌患者术后1年生存率的预测价值. 北京: 北京协和医学院, 2017.
14.	Chawla A, Huang TL, Ibrahim AM, et al. Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer. HPB (Oxford), 2018, 20(5): 398-404.
15.	Shirai Y, Shiba H, Sakamoto T, et al. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Surgery, 2015, 158(2): 360-365.
16.	Wang Y, Cui C, Yu Q, et al. Development and validation of a nomogram for predicting survival in patients with pancreatic ductal adenocarcinoma after radical pancreatoduodenectomy. Oncologie, 2023, 25(1): 51-59.
17.	Giakoustidis A, Neofytou K, Costa Neves M, et al. Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg, 2018, 22(3): 197-207.
18.	Ye S, Bai L. Comparison and validation of the value of preoperative inflammation marker-based prognostic scores in resectable pancreatic ductal adenocarcinoma. Cancer Manag Res, 2018, 10: 3405-3417.
19.	孙婧, 史幼梧, 贾军, 等. 血液炎症相关指标在晚期胰腺癌中的预后价值. 首都医科大学学报, 2022, 43(2): 299-304.
20.	徐雪君, 周天朔, 李志伟. 系统性炎症指标对胰腺癌预后的价值研究. 癌症进展, 2019, 17(23): 2774-2776.
21.	Miyashita T, Tajima H, Makino I, et al. Metastasis-promoting role of extravasated platelet activation in tumor. J Surg Res, 2015, 193(1): 289-294.
22.	刘荣华, 王婷, 张焜和. 外周血炎性指标对胰腺癌患者预后预测价值的研究进展. 癌症进展, 2022, 20(10): 990-992, 1023.
23.	周雨, 林叶, 简志祥. 治疗前血小板水平与胰腺癌预后相关性的Meta分析. 循证医学, 2017, 17(6): 343-349.
24.	Elaskalani O, Falasca M, Moran N, et al. The role of platelet-derived adp and atp in promoting pancreatic cancer cell survival and gemcitabine resistance. Cancers (Basel), 2017, 9(10): 142.
25.	孙彬, 李健. 血小板在恶性肿瘤转移中的机制. 军医进修学院学报, 2011, 32(8): 871-873.
26.	程娟, 管世鹤, 陈礼文, 等. 胰腺癌患者手术前后外周血淋巴细胞亚群和血小板变化. 检验医学, 2020, 35(7): 655-659.

1. 王海静, 秦芳. 外周血FAR联合NLR在局部晚期或转移性胰腺癌患者预后评估中的价值. 国际检验医学杂志, 2022, 43(13): 1587-1592, 1597.
2. Toledano-Fonseca M, Cano MT, Inga E, et al. The combination of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio with liquid biopsy biomarkers improves prognosis prediction in metastatic pancreatic cancer. Cancers (Basel), 2021, 13(6): 1210.
3. Gleisner AL, Assumpcao L, Cameron JL, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?. Cancer, 2007, 110(11): 2484-2492.
4. Klein F, Puhl G, Guckelberger O, et al. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol Res Pract, 2012, 2012: 939350.
5. Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol, 2007, 14(1): 118-127.
6. Chen X, Yi B, Liu Z, et al. Global, regional and national burden of pancreatic cancer, 1990 to 2017: results from the Global Burden of Disease Study 2017. Pancreatology, 2020, 20(3): 462-469.
7. Singh N, Baby D, Rajguru JP, et al. Inflammation and cancer. Ann Afr Med, 2019, 18(3): 121-126.
8. Sideras K, Braat H, Kwekkeboom J, et al. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev, 2014, 40(4): 513-522.
9. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst, 2014, 106(6): dju124.
10. 钱佳璐, 汤娜. 血小板与淋巴细胞比值联合CA19-9预测胰腺癌预后. 现代消化及介入诊疗, 2022, 27(4): 512-515.
11. 谢小妹, 陈龙, 黄江琼, 等. 术前血清CEA水平与非小细胞肺癌预后关系的Meta分析. 现代生物医学进展, 2012, 12(19): 3689-3692.
12. 唐伟杰. NLR和PLR对根治性胰腺癌切除术术后生存期的预测价值. 芜湖: 皖南医学院, 2022.
13. 申鹏. 术前NLR、PLR对胰腺癌患者术后1年生存率的预测价值. 北京: 北京协和医学院, 2017.
14. Chawla A, Huang TL, Ibrahim AM, et al. Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer. HPB (Oxford), 2018, 20(5): 398-404.
15. Shirai Y, Shiba H, Sakamoto T, et al. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Surgery, 2015, 158(2): 360-365.
16. Wang Y, Cui C, Yu Q, et al. Development and validation of a nomogram for predicting survival in patients with pancreatic ductal adenocarcinoma after radical pancreatoduodenectomy. Oncologie, 2023, 25(1): 51-59.
17. Giakoustidis A, Neofytou K, Costa Neves M, et al. Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg, 2018, 22(3): 197-207.
18. Ye S, Bai L. Comparison and validation of the value of preoperative inflammation marker-based prognostic scores in resectable pancreatic ductal adenocarcinoma. Cancer Manag Res, 2018, 10: 3405-3417.
19. 孙婧, 史幼梧, 贾军, 等. 血液炎症相关指标在晚期胰腺癌中的预后价值. 首都医科大学学报, 2022, 43(2): 299-304.
20. 徐雪君, 周天朔, 李志伟. 系统性炎症指标对胰腺癌预后的价值研究. 癌症进展, 2019, 17(23): 2774-2776.
21. Miyashita T, Tajima H, Makino I, et al. Metastasis-promoting role of extravasated platelet activation in tumor. J Surg Res, 2015, 193(1): 289-294.
22. 刘荣华, 王婷, 张焜和. 外周血炎性指标对胰腺癌患者预后预测价值的研究进展. 癌症进展, 2022, 20(10): 990-992, 1023.
23. 周雨, 林叶, 简志祥. 治疗前血小板水平与胰腺癌预后相关性的Meta分析. 循证医学, 2017, 17(6): 343-349.
24. Elaskalani O, Falasca M, Moran N, et al. The role of platelet-derived adp and atp in promoting pancreatic cancer cell survival and gemcitabine resistance. Cancers (Basel), 2017, 9(10): 142.
25. 孙彬, 李健. 血小板在恶性肿瘤转移中的机制. 军医进修学院学报, 2011, 32(8): 871-873.
26. 程娟, 管世鹤, 陈礼文, 等. 胰腺癌患者手术前后外周血淋巴细胞亚群和血小板变化. 检验医学, 2020, 35(7): 655-659.

West China Medical Journal

Relationship between preoperative platelet-to-lymphocyte ratio and prognosis in patients with pancreatic ductal adenocarcinoma: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content